Shares of Iovance Biotherapeutics Inc (NASDAQ:IOVA) have received an average rating of “Buy” from the fourteen analysts that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, twelve have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $30.20.

IOVA has been the subject of several research reports. Robert W. Baird increased their price objective on shares of Iovance Biotherapeutics from $29.00 to $34.00 and gave the company an “outperform” rating in a report on Thursday, May 16th. B. Riley set a $2.00 price objective on shares of Ascena Retail Group and gave the company a “hold” rating in a report on Friday, May 17th. ValuEngine downgraded shares of Verso from a “hold” rating to a “sell” rating in a report on Thursday, May 23rd. Oppenheimer set a $32.00 price objective on shares of Iovance Biotherapeutics and gave the company a “buy” rating in a report on Wednesday, July 3rd. Finally, Wells Fargo & Co increased their price objective on shares of Iovance Biotherapeutics from $23.00 to $32.00 and gave the company an “outperform” rating in a report on Thursday, May 23rd.

Shares of IOVA traded down $0.02 during midday trading on Friday, hitting $23.91. 874,851 shares of the company traded hands, compared to its average volume of 1,914,696. The firm has a 50 day simple moving average of $20.77. Iovance Biotherapeutics has a 52 week low of $7.26 and a 52 week high of $25.50. The stock has a market cap of $2.95 billion, a PE ratio of -18.83 and a beta of 1.77. The company has a debt-to-equity ratio of 0.01, a quick ratio of 20.09 and a current ratio of 20.09.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.01). On average, equities analysts anticipate that Iovance Biotherapeutics will post -1.19 EPS for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Exane Derivatives purchased a new stake in shares of Iovance Biotherapeutics during the 2nd quarter valued at about $191,000. Advisor Group Inc. raised its position in shares of Iovance Biotherapeutics by 58.6% during the 4th quarter. Advisor Group Inc. now owns 8,118 shares of the biotechnology company’s stock valued at $72,000 after buying an additional 3,000 shares in the last quarter. Kalos Management Inc. purchased a new stake in shares of Iovance Biotherapeutics during the 4th quarter valued at about $93,000. Virtu Financial LLC purchased a new stake in shares of Iovance Biotherapeutics during the 1st quarter valued at about $99,000. Finally, Moors & Cabot Inc. purchased a new stake in shares of Iovance Biotherapeutics during the 1st quarter valued at about $126,000. Hedge funds and other institutional investors own 94.96% of the company’s stock.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.

Further Reading: Dividend Achievers

Analyst Recommendations for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.